Impact of steroid-avoidance immunosuppression on long-term outcome after liver transplantation for HCV cirrhosis: The need for well documented long-term follow-up

Acta Gastro-Enterologica Belgica

Volumn 75, Issue 4, 2012, Pages 411-418

  Bonaccorsi Riani, E ^a   Sempoux, Ch ^b   Piette, N ^a   Julliard, O ^a   Kabamba, B ^b   Ciccarelli, O ^a   Roggen, Fr ^a   De Reyck, Ch ^a   Hassoun, Z ^b   Lerut, Jan ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Disease recurrence; HCV infection; Immunosuppression; Liver transplantation; Minimal immunosuppression; Steroid avoidance

Indexed keywords

AZATHIOPRINE; HYDROCORTISONE SODIUM SUCCINATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; STEROID; TACROLIMUS; ANTIVIRUS AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MALE; MONOTHERAPY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; SURVIVAL; TRANSPLANTATION; TREATMENT OUTCOME; BIOPSY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GRAFT REJECTION; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; TIME;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIVIRAL AGENTS; BIOPSY; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; RECURRENCE; SURVIVAL ANALYSIS; TACROLIMUS; TIME; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875009638     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. www.eltr.org
2. FERAY C., CACCAMO L., ALEXANDER G.J., DUCOT B., GUGENHEIM J., CASANOVAS T. et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastro-enterology, 1999, 117: 619-625.
3. GANE E.J. The natural history of recurrent hepatitis C and what influences this. Liver Transpl., 2008, 14S2: S36-44.
4. BERENGUER M. Hepatitis C after liver transplantation: risk factors, outcomes and treatment. Curr. Opin. Organ. Transpl., 2005, 10: 81-89.
5. POYNARD T. Natural history of liver fibrosis progression in patients with chronic hepatitis. Lancet, 1997, 349: 825-832.
6. ROCHE B., SAMUEL D. Risk factors for hepatitis C recurrence after liver transplantation. J. Virol. Hepat., 2007, 14S1: 89-96.
7. GHOBRIAL R.M., STEADMAN R., GORNBEIN J., LASSMAN C., HOLT C.D., CHEN P. et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann. Surg., 2001, 234: 384-394.
8. LERUT J., MATHYS J., VERBAANDERT C., TALPE S., CICCARELLI O., LEMAIRE J. et al. Tacrolimus monotherapy in liver transplantation: One year results of a prospective, randomized, double-blind, placebo-controlled study. Ann. Surg., 2008, 248: 956-967.
9. LERUT J.P., MOLLE G., DONATACCIO M., DE KOCK M., CICCARELLI O., LATERRE P.F. et al. Cavocaval liver transplantation without venovenous bypass and without temporary portocaval shunting: the ideal technique for adult liver grafting? Transpl. Int., 1997, 10: 171-179.
10. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology, 1997, 25: 658-663.
11. LUDWIG J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology, 1993, 105: 274-278.
12. BERARDI S., LODATO F., GRAMENZI A., D'ERRICO A., LENZI M., BONTADINI A. et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut, 2007, 56: 237-242.
13. ROCHE B., SEBAGH M., CANFORA M.L., ANTONINI T., ROQUE-AFONSO A.M., DELVART V. et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl., 2008, 14: 1766-1777.
14. LERUT J., BONACCORSI-RIANI E., FINET P., GIANELLO P. Minimization of steroids in liver transplantation. Transpl. Int., 2009, 22: 2-19.
15. BERENGUER M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl., 2003, 9: S44-47.
16. BERENGUER M., PRIETO M., SAN JUAN F., RAYÓN J.M., MARTINEZ F., CARRASCO D. et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology, 2002, 36: 202-210.
17. CESCON M., GRAZI G.L., CUCCHETTI A., RAVAIOLI M., ERCOLANI G., VIVARELLI M. et al. Improving the outcome of liver transplantation with very old donors with updated selection and management criteria. Liver Transpl., 2008, 14: 672-679.
18. GEDALY R., CLIFFORD T.M., MC HUGH P.P., JEON H., JOHNSON T.D., RANJAN D. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multicenter international survey. Transpl. Int., 2008, 21: 867-872.
19. BERENGUER M., FERREL L., WATSON J., PRIETO M., KIM M., RAYÓN M. et al. HCV-related fibrosis progression after liver transplantation: increase in recent years. J. Hepatol., 2000, 32: 673-684.
20. FIRPI R.J., ZHU H., MORELLI G., ABDELMALEK M.F., SOLDEVILA-PICO C., MACHICAO V.I. et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl., 2006, 12: 51-57.
21. MC ALISTER V.S., HADDAD E., RENOUF E., MALTHANER R.A., KJAER M.S., GLUUD L.L. Cyclosporin versus tacrolimus as primary immunosuppresant after liver transplantation: a meta-analysis. Am. J. Transpl., 2006, 6: 1578-1585.
22. STANGL J.R., CARROLL K.L., ILLICHMANN M., STRIKER R. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation, 2004, 77: 562-567.
23. SAMONAKIS D.N., TRIANTOS C.K., THALHEIMER U., QUAGLIA A., LEANDRO G., TEIXEIRA R. et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl., 2005, 11: 386-395.
24. SEGEV D., SOZIO S., SHIN E., NAZARIAN S.M., NATHAN H., THULUVATH P.J. et al. Steroid avoidance in liver transplantation: metaanalysis and meta-regression of randomised trials. Liver Transpl., 2008, 14: 512-525.
25. BROWN R.S. Steroids in recurrent hepatitits C following liver transplantation: pitfall or panacea. J. Hepatol., 2007, 47: 741-743.
26. BERENGUER M., AGUILERA V., PRIETO M., SAN JUAN F., RAYÓN J.M., BENLLOCH S. et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J. Hepatol., 2006, 44: 717-722.
27. VIVARELLI M., BURRA P., LA BARBA G., CANOVA D., SENZOLO M., CUCCHETTI A. et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J. Hepatol., 2007, 47: 793-798.
28. HUMAR A., CROTTEAU S., GRUESSNER A., KANDASWAMY R., GRUESSNER R., PAYNE W. et al. Steroid minmization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes. Clin. Transplant., 2007, 21: 526-531.
29. FILIPPONI F., CALLEA F., SALIZZONI M., GRAZI GL., FASSATI L.R., ROSSI M. Double-blind comparison of hepatitis C histological recurrence rate in HCV positive liver transplant recipients given basiliximab and steroids or basiliximab and placebo, in addition to cyclosporine and azathioprine. Transplantation, 2004, 78: 1488-1495.
30. MARCOS A., EGHTESAD B., FUNG J.J., FONTES P., PATEL K., DEVERA M. et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation, 2004, 78: 966-971.
31. MARGARIT C., BILBAO I., CASTELLS L., LOPEZ I., POU L., ALLENDE E. et al. A prospective randomised trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl. Int., 2005, 18: 1336-1345.
32. MARUBASHI S., DONO K., AMANO K., HAMA N., GOTOH K., TAKAHASHI H. et al. Steroid-free living-donor liver transplantation in adults. Transplantation, 2005, 80: 704-706.
33. DE RUVO N., CUCCHETTI A., LAURO A., MASETTI M., CAUTERO N., DI BENEDETTO F. et al. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pre-treatment and hepatitis C virus recurrence in liver transplantation. Transplantation, 2005, 80: 8-12.
34. LLADO L., XIOL X., FIGUERAS J., RAMOS E., MEMBA R., SERRANO T. et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomised study. J. Hepatol., 2006, 44: 710-716.
35. LLADO L., FABREGAT J., CASTELLOTE J., RAMOS E., XIOL X., TORRAS J. et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl., 2008, 14: 1752-1760.
36. SAMONAKIS D.N., MELA M., QUAGLIA A., TRIANTOS C.K., THALHEIMER U., LEANDRO G. et al. Rejection rate in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl. Infect. Dis., 2006, 81: 3-12.
37. KATO T., GAYNOR J.J., YOSHIDA H., MONTALVANO M., TAKAHASHI H., PYRSOPOULOS N. et al. Randomized trial of steroidfree induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus impact on hepatic fibrosis progression at one year. Transplantation, 2007, 84: 829-835.
38. KLINTMALM B.G., WASHBURN W.K., RUDICH S.M., HEFFRON T.G., TEPERMAN L.W., FASOLA C. et al. Corticosteroid-free immuno-suppression with daclizumab in HCV positive liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl., 2007, 13: 1521-1531.
39. NEUMANN U.P., BERG T., BAHRA M., SEEHOFER D., LANGREHR J.M., NEUHAUS R. et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J. Hepatol., 2004, 41: 830-836.
40. BERENGUER M., RAYÓN JM., PRIETO M., AGUILERA V., NICOLAS D., ORTIZ V., CARRASCO D. et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl., 2001, 7: 790-796.
41. FIRPI R.J., ABDELMALEK M.F., SOLDEVILA-PICO C., CABRERA R., SHUSTER J.J., THERIAQUE D. et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl., 2004, 10: 1240-1247.
42. DUVOUX C., PAWLOTSKY J.M., CHERQUI D., TRANVAN NHIEU J., METREAU J.M., FAGNIEZ P.L. et al. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. Transplantation, 1995, 60: 457-461.
43. GANE E.J., NAOUMOV N.V., QIAN K.P., MONDELLI M.U., MAERTENS G., PORTMAN B.C. et al. A longitudinal analysis of hepatitis C virus replication following live transplantation. Gastroenterology, 1996, 110: 167-177.
44. CHARLTON M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl., 2003, 9: S58-62.
45. KUO A., TAN V., LAN B., KHALIL M., FENG S., ROBERT J.P. et al. Longterm histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl., 2008, 14: 1491-1497.
46. FIRPI R.J., NELSON D.R. Current and future hepatitis C therapies. Arch. Med. Res., 2007, 38: 678-690.
47. ORLANDO G., MANZIA T., BAIOCCHI L., SANCHEZ-FUEYO A., ANGELICO M., TISONE G. The Tor Vergata weaning off immuno-suppression protocol in stable HCV liver transplant patients: the up-dated follow up at 78 months. Transpl. Immunol., 2008, 20: 43-47.